Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. The Tranche 2 shares subscription and
allocation have been completed on 20 August 2025.
Related Questions
How will the completion of Tranche 2 affect IDEX’s short‑term liquidity and price action?
What dilution impact does the 9,090,909‑share private placement have on existing shareholders and earnings per share?
What are the strategic reasons behind the NOK 3.30 pricing and how does it compare to recent market valuations of IDEX and its peers?